What PT and aPTT are actually measuring

PT and aPTT are clot-based assays performed on citrated platelet-poor plasma. Each reports the time in seconds from the addition of its method-specific activating reagent to visible fibrin-clot formation on the analyzer's detection system. PT initiates clotting through a thromboplastin (tissue factor) reagent; aPTT initiates through a contact-activation reagent and phospholipid. Both measure a functional endpoint, not a drug concentration and not a single factor level.

Because each assay is a race to a clot, anything that slows any step in the pathway feeding that endpoint prolongs the result: a missing or reduced clotting factor, an inhibitor of a factor, or a drug that blocks a step directly. The assay cannot distinguish among those causes by itself. A prolonged aPTT is evidence of delayed clot formation in that specific system, not a diagnosis.

The four anticoagulant classes act at different points upstream of that shared endpoint. Vitamin K antagonists reduce hepatic synthesis of functional factors II, VII, IX, and X, an indirect and multi-factor effect. Unfractionated and low-molecular-weight heparin accelerate antithrombin, which inactivates thrombin (factor IIa) and factor Xa, again indirect. Direct thrombin inhibitors such as dabigatran bind free and clot-bound thrombin directly. Factor Xa inhibitors such as apixaban, rivaroxaban, and edoxaban bind factor Xa directly. See the diagram below.

This is the mental model to carry into every result: name the mechanism, then ask which clot-based or chromogenic test is built to be sensitive to that mechanism. A test that is insensitive to a given class will look reassuring even when the drug is present at a clinically relevant level, and that gap is where most interpretation errors happen.

Match the mechanism to the test before reading the number, because a normal result on the wrong test proves nothing about the drug you are looking for.